Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.63 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.61 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.57 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.57 |
| ▸ | CXCL8 | P10145 | 6/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30268594 | 0.92 | IL23R (0.66) | IL23RKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL29973644 | 0.89 | KISS1R (0.66) | IL23RKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL31307225 | 0.89 | IL23R (0.65) | IL23RKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL31468796 | 0.88 | KISS1R (0.64) | IL23RKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL34470137 | 0.88 | KISS1R (0.67) | IL23RKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL30398408 | 0.87 | NPY1R (0.65) | KISS1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31410855 | 0.87 | KISS1R (0.65) | IL23RKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL38661114 | 0.87 | KISS1R (0.62) | IL23RKISS1RCXCL8DPP3 | |
| SCHEMBL30988898 | 0.86 | CTSL (0.56) | IL23RKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL30878079 | 0.86 | KISS1R (0.65) | IL23RKISS1RNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137206-A1 | NOVEL LIGAND GUIDED BLOCK COPOLYMERS FOR TARGETED DRUG DELIVERY | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100137206-A1 | NOVEL LIGAND GUIDED BLOCK COPOLYMERS FOR TARGETED DRUG DELIVERY | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137206-A1 | NOVEL LIGAND GUIDED BLOCK COPOLYMERS FOR TARGETED DRUG DELIVERY | EBPL, EDNRB, BMPR1B | IL23R 2572/4885KISS1R 3814/4885NPY1R 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.